Palisade Bio, Inc.
PALIHealthcareNASDAQBiotechnology · Last scanned May 30, 2026
Scan Results
Daily timeframePalisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the. At a $368.4M market cap, Palisade Bio, Inc. ranks as a small-cap company within healthcare. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease.
Market Cap
$368.4M
Beta
—
P/E (TTM)
17.67
P/E (Fwd)
-9.02
EPS (TTM)
$0.12
EPS (Fwd)
$-0.23
ROE
-36.4%
ROA
-23.4%
Cash
$132.6M
Total Debt
$0
Free CF
-$9.6M
52W Change
179.0%
Annual Financials
Cash vs Debt
Palisade Bio, Inc. reports $132.6M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$9.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -36.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Palisade Bio, Inc.'s trajectory.